These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 12215319

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women.
    Cheng WC, Yen ML, Hsu SH, Chen KH, Tsai KS.
    Endocrine; 2004; 23(2-3):215-8. PubMed ID: 15146102
    [Abstract] [Full Text] [Related]

  • 3. Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.
    Duntas LH, Mantzou E, Koutras DA.
    Thyroid; 2001 Aug; 11(8):779-82. PubMed ID: 11525272
    [Abstract] [Full Text] [Related]

  • 4. The effect of raloxifene on glyco-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study.
    Cucinelli F, Soranna L, Romualdi D, Muzj G, Mancuso S, Lanzone A.
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4186-92. PubMed ID: 12213869
    [Abstract] [Full Text] [Related]

  • 5. Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles.
    Hsu SH, Cheng WC, Jang MW, Tsai KS.
    Clin Chem; 2001 Oct; 47(10):1865-7. PubMed ID: 11568106
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G.
    Maturitas; 2005 Apr 11; 50(4):321-30. PubMed ID: 15780533
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels.
    Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M.
    Menopause; 2000 Apr 11; 7(4):243-50. PubMed ID: 10914617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Follicle stimulating hormone, its novel association with sex hormone binding globulin in men and postmenopausal women.
    Wang N, Zhang K, Han B, Li Q, Chen Y, Zhu C, Chen Y, Xia F, Zhai H, Jiang B, Shen Z, Lu Y.
    Endocrine; 2017 Jun 11; 56(3):649-657. PubMed ID: 28260206
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
    Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A.
    Breast Cancer Res Treat; 2006 Jul 11; 98(2):167-72. PubMed ID: 16538534
    [Abstract] [Full Text] [Related]

  • 19. Antiestrogenic properties of raloxifene.
    Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL.
    Pharmacology; 1995 Apr 11; 50(4):209-17. PubMed ID: 7792309
    [Abstract] [Full Text] [Related]

  • 20. Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.
    Lambrinoudaki IV, Christodoulakos GE, Economou EV, Vlachou SA, Panoulis CP, Alexandrou AP, Kouskouni EE, Creatsas GC.
    Maturitas; 2008 Jan 20; 59(1):62-71. PubMed ID: 18164562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.